Literature DB >> 15917410

Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour.

G M K Tse1, F C Wong, A K H Tsang, C S Lee, P C W Lui, A W I Lo, B K B Law, R A Scolyer, R Z Karim, T C Putti.   

Abstract

BACKGROUND: Nitric oxide synthase (NOS), particularly endothelial and inducible forms (e/i-NOS), are expressed in various cancers, including breast cancer. In mammary fibroepithelial lesions, NOS expression in stromal cells has been reported to be lower in fibroadenomas than in phyllodes tumours. AIMS: To investigate NOS expression in phyllodes tumours of varying degrees of malignancy.
METHODS: One hundred and sixty seven mammary phyllodes tumours (97 benign, 47 borderline malignant, and 23 frankly malignant) were evaluated for e-NOS and i-NOS expression by immunohistochemistry. Correlations with previously reported expression of stromal vascular growth factor (VEGF) and microvessel density were also performed.
RESULTS: Stromal expression of e-NOS was absent, weak, moderate, and strong in 43%, 31%, 13%, and 13% of benign tumours; 17%, 26%, 13%, and 44% of borderline malignant tumours; and 17%, 35%, 13%, and 35% of frankly malignant tumours, respectively. Stromal expression of i-NOS was 77%, 18%, 4%, and 1% in benign tumours; 42%, 28%, 19%, and 11% in borderline malignant tumours; and 43%, 13%, 26%, and 18% in frankly malignant tumours, respectively. Stromal expression of both i-NOS and e-NOS was significantly different between the benign and malignant (borderline and frank) groups of phyllodes tumours (p < 0.0001). Furthermore, the expression of i-NOS correlated with stromal VEGF expression and microvessel density. The expression of NOS in the epithelial cells was strong, and showed no differences between the different groups of tumours.
CONCLUSIONS: Higher stromal expression of NOS in phyllodes tumours is associated with malignancy, suggesting a possible role in malignant progression, particularly metastasising potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917410      PMCID: PMC1770683          DOI: 10.1136/jcp.2004.023028

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  41 in total

1.  Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression.

Authors:  Boel De Paepe; Valerie M Verstraeten; Christian R De Potter; Gillian R Bullock
Journal:  Histochem Cell Biol       Date:  2001-12-22       Impact factor: 4.304

2.  eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma.

Authors:  M Vakkala; P Paakko; Y Soini
Journal:  Int J Oncol       Date:  2000-10       Impact factor: 5.650

3.  Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer.

Authors:  J H Martin; S Begum; O Alalami; A Harrison; K W Scott
Journal:  Tumour Biol       Date:  2000 Mar-Apr

4.  Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas.

Authors:  M Vakkala; K Kahlos; E Lakari; P Pääkkö; V Kinnula; Y Soini
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

5.  Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence.

Authors:  J H Martin; O Alalami; H W van den Berg
Journal:  Cancer Lett       Date:  1999-09-20       Impact factor: 8.679

6.  Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors.

Authors:  S Reveneau; L Arnould; G Jolimoy; S Hilpert; P Lejeune; V Saint-Giorgio; C Belichard; J F Jeannin
Journal:  Lab Invest       Date:  1999-10       Impact factor: 5.662

7.  Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors.

Authors:  Gary M K Tse; Philip C W Lui; Richard A Scolyer; Thomas C Putti; Fred Y L Kung; Bonita K B Law; Tai-Shing Lau; C Soon Lee
Journal:  Mod Pathol       Date:  2003-10       Impact factor: 7.842

8.  Expression of inducible nitric oxide synthase in bone metastases.

Authors:  P A Brennan; S Sharma; J R Bowden; T Umar
Journal:  Eur J Surg Oncol       Date:  2003-09       Impact factor: 4.424

9.  Increased p53 protein expression in malignant mammary phyllodes tumors.

Authors:  Gary M K Tse; Thomas C Putti; Fred Y L Kung; Richard A Scolyer; Bonita K B Law; Tai-Shing Lau; C Soon Lee
Journal:  Mod Pathol       Date:  2002-07       Impact factor: 7.842

10.  Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy.

Authors:  Sibylle Loibl; Gunter von Minckwitz; Sonja Weber; Hans-Peter Sinn; Valérie B Schini-Kerth; Irina Lobysheva; Françoise Nepveu; Georg Wolf; Klaus Strebhardt; Manfred Kaufmann
Journal:  Cancer       Date:  2002-09-15       Impact factor: 6.860

View more
  8 in total

1.  Myenteric denervation in gastric carcinogenesis: differential modulation of nitric oxide and annexin-A1.

Authors:  Ana Cláudia Polli-Lopes; Cássia F Estofolete; Sonia M Oliani; Sérgio Zucoloto; Fernando Q Cunha; Cristiane D Gil
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

Review 2.  NO to breast: when, why and why not?

Authors:  Shehla Pervin; Gautam Chaudhuri; Rajan Singh
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 3.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Authors:  James Leiper; Manasi Nandi
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

4.  Nitrosothiol Signaling in Anoikis Resistance and Cancer Metastasis.

Authors:  Sudjit Luanpitpong; Anand Krishnan V Iyer; Neelam Azad; Liying Wang; Yon Rojanasakul
Journal:  For Immunopathol Dis Therap       Date:  2012-01-01

5.  Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice.

Authors:  Nora A Mohamad; Graciela P Cricco; Lorena A Sambuco; Máximo Croci; Vanina A Medina; Alicia S Gutiérrez; Rosa M Bergoc; Elena S Rivera; Gabriela A Martín
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

6.  Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells.

Authors:  Hui-Chin Wen; Chih-Pin Chuu; Chen-Yu Chen; Shine-Gwo Shiah; Hsing-Jien Kung; Kuang-Liang King; Liang-Chen Su; Shi-Chuan Chang; Chung-Ho Chang
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

Review 7.  Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.

Authors:  Patrizia Di Iorio; Maurizio Ronci; Patricia Giuliani; Francesco Caciagli; Renata Ciccarelli; Vanni Caruso; Sarah Beggiato; Mariachiara Zuccarini
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

8.  Gene network and pathway analysis of bovine mammary tissue challenged with Streptococcus uberis reveals induction of cell proliferation and inhibition of PPARgamma signaling as potential mechanism for the negative relationships between immune response and lipid metabolism.

Authors:  Kasey M Moyes; James K Drackley; Dawn E Morin; Massimo Bionaz; Sandra L Rodriguez-Zas; Robin E Everts; Harris A Lewin; Juan J Loor
Journal:  BMC Genomics       Date:  2009-11-19       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.